Company Filing History:
Years Active: 2022
Title: Innovator Ying He: Pioneering Chemotherapy Identification Methods in Munich
Introduction
Ying He, an innovative inventor based in Munich, Germany, has made significant strides in the medical field with his groundbreaking patent. As a talented individual in the research and healthcare sector, he focuses on improving treatment methods for patients undergoing chemotherapy.
Latest Patents
Ying He holds a patent titled, "Methods of identifying an individual to be treated by chemotherapy based on cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) marker molecules and related uses." This patent introduces a method to identify individuals diagnosed with non-small cell lung carcinoma who are eligible for chemotherapy treatment. By utilizing specific marker molecules, specifically CYFRA 21-1 and CEA, healthcare professionals can make informed treatment decisions that potentially improve patient outcomes.
Career Highlights
Currently, Ying He is employed at Roche Diagnostics Operations, Inc., a leader in the healthcare diagnostics industry. His work at Roche signifies a commitment to advancing medical technology and enhancing patient care through innovation. His invention stands as a testament to his expertise and dedication to fighting challenging diseases like cancer.
Collaborations
Throughout his career, Ying He has collaborated with esteemed colleagues such as Friedemann Krause and Vinzent Rolny. Collaborations with other talented professionals in his field contribute valuable perspectives and expertise, enriching his work and fostering advancements in medical diagnosis and treatment.
Conclusion
Ying He's contributions, particularly in the realm of chemotherapy treatment identification, highlight the crucial role of inventors in transforming healthcare practices. His innovation not only reflects his dedication to improving patient care but also inspires ongoing advancements in the medical field. As research continues, the impact of his work is bound to resonate throughout the medical community, providing a pathway for future breakthroughs in cancer treatment methodologies.